Evidence map›Paper›PMID 38180685›Full record

ArticleImmunologic research2024

Response to: regarding the significance of anti-COVID-IgA antibody response in COVID-19 breakthrough infection.

Sabiha Anis, Mariam Ashfaq Khan, Areej Fatima, Fatima Kanani, Javeria Aijaz, Aneela Hussain, Samreen Sarfaraz

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sabiha AnisImmunology Section, Department of Pathology and Department of Medicine & Allied, Indus Hospital and Health Network, Karachi, 75190, Pakistan. sabiha.anis@tih.org.pk.ORCID 0000-0003-4281-2608
Mariam Ashfaq KhanIndus Hospital and Research Center, Indus Hospital and Health Network, Karachi, 75190, Pakistan.ORCID 0000-0002-4445-8959
Areej FatimaImmunology Section, Department of Pathology, Indus Hospital and Health Network, Karachi, 75190, Pakistan.
Fatima KananiChemical Pathology Section, Department of Pathology, Indus Hospital and Health Network, Karachi, 75190, Pakistan.ORCID 0000-0001-6486-8886
Javeria AijazMolecular Biology Section, Department of Pathology, Indus Hospital and Health Network, Karachi, 75190, Pakistan.ORCID 0000-0003-4401-4677
Aneela HussainInfectious Diseases Department, Indus Hospital and Health Network, Karachi, 75190, Pakistan.
Samreen SarfarazInfectious Diseases Department, Indus Hospital and Health Network, Karachi, 75190, Pakistan.
Indus Hospital · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In response to Chen et al.'s comments on our paper regarding the significance of anti-COVID-IgA antibody response in COVID-19 breakthrough infection in vaccinated patients, we have highlighted the role and the scope of this paper in this correspondence. The role of anti-COVID-19-IgA is already known. The objective of the previous study was to see its role in breakthrough-infected patients. To analyse this effect, we recruited patients with COVID-19 infection after they were fully vaccinated and compared them with the vaccinated group who did not get the infection. Both groups were equally exposed to the virus as all of them were health care workers. We also showed that the anti-COVID-19-NP-IgA was absent in the healthy cohort of our study groups, signifying the absence of natural infection in them during this period. The article also highlights the importance of vaccinating all individuals including those who are immunosuppressed, as it prevents severe COVID-19 infection in these individuals. The physicians should be aware of the fact that immunosuppressed patients are more likely to get COVID-19 breakthrough infection. However, proper vaccination with booster doses prevents severe infection in them.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunoglobulin ASARS-CoV-2Antibody FormationBreakthrough InfectionsHumansImmunocompromised HostVaccinationAntibodies, ViralCOVID-19 VaccinesImmunoglobulin AAnti-COVID-19-IgA antibodiesBreakthrough infectionCOVID-19 vaccinationSevere COVID-19 infection

Identifiers

PMID38180685
OpenAlexW4390618481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.